UK government aims to include biosimilars in price controls

The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that would include biosimilars in the scope of its price controls. The statutory scheme covers those companies who don’t sign on to the voluntary Pharmaceutical Price Regulation Scheme (PPRS). To coincide with the new PPRS scheme, expected to come into

Continue Reading